跳至主要内容
临床试验/NCT02407496
NCT02407496已完成不适用

Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD)

Think Now Incorporated1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2014年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
80
试验地点
1
主要终点
NAT Slow Fluctuation Measure

研究概览

简要总结

The purpose of this study is develop a new assessment tool for Attention Deficit-Hyperactivity Disorder (ADHD) and to then test its validity (i.e. ability to discriminate between individuals with ADHD and healthy controls).

详细描述

The purpose of this study is to develop a novel approach and software for analyzing electroencephalography (EEG) data to identify biomarkers of ADHD. Then to test the ability of this assessment tool to differentiate between adults with ADHD and healthy controls by comparing the classification accuracy of the metrics from the new tool to the classification accuracy of existing behavioral tests for ADHD.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Specific inclusion criteria for ADHD are:
  • meet established DSM-5 criteria for ADHD predominately inattentive or combined subtype with clinically significant levels of impairment, diagnosed by structured clinical interview, the Mini International Neuropsychiatric Interview, and corroborating information
  • Clinical Global Impression-Severity (CGI-S) score ≥ 4 for ADHD
  • no lifetime history of DSM-5 bipolar disorder, psychotic disorder, pervasive developmental disorder, obsessive-compulsive disorder, substance abuse, or substance dependence (except nicotine) as assessed wit the MINI
  • able in the opinion of the investigator to complete all required study procedures.

排除标准

  • Exclusion criteria for both groups are:
  • History of diagnosis of childhood disorder other than ADHD (e.g. autism, dyslexia)
  • history of any general medical condition likely to require chronic use of medication with identified CNS effects suspected to alter cognitive performance
  • history of seizure disorder, brain tumor, other major neurological disorder or head injury resulting in loss of consciousness
  • serious oxygen deprivation
  • current psychopathology requiring ongoing treatment with antipsychotic medications, mood stabilizers, benzodiazepines, or anticonvulsants
  • current untreated psychopathology which is rated to be primary in terms of severity (greater than ADHD severity)
  • current treatment with guanfacine.

结局指标

主要结局

NAT Slow Fluctuation Measure

时间窗: A single measurement is made for each individual at DAY 1 - the time of the brain wave test.

The NAT EEG test simultaneously generates 2 EEG values and 1 behavioral value that are used together as an assessment metric for ADHD. This is a one-time measure to assess its magnitude in ADHD vs Controls.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Principal Investigator
主要研究者

Gregory Simpson, Ph.D.

Chief Scientific Officer

Think Now Incorporated

研究点 (1)

Loading locations...

相似试验